卵巢癌新药-话题@MedSci

#卵巢癌新药#

6篇内容 | 606人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1989743, encodeId=e3501989e431d, content=<a href='/topic/show?id=05ac3686ec6' target=_blank style='color:#2F92EE;'>#卵巢癌新药#</a>, objectTitle=卵巢癌新药纳入医保专家：患者月均自付费用低至两三千元, objectType=article, longId=208021, objectId=3d01208021e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d01208021e0, replyNumber=0, likeNumber=29, createdTime=2022-02-07, rootId=0, userName=lisa438, userId=373b263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d01208021e0, moduleTitle=卵巢癌新药纳入医保专家：患者月均自付费用低至两三千元, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d01208021e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1989742, encodeId=10391989e42b6, content=<a href='/topic/show?id=05ac3686ec6' target=_blank style='color:#2F92EE;'>#卵巢癌新药#</a>, objectTitle=阿斯利康卵巢癌新药获FDA批准！, objectType=article, longId=110453, objectId=cdf211045387, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=cdf211045387, replyNumber=0, likeNumber=30, createdTime=2017-10-08, rootId=0, userName=lisa438, userId=373b263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=cdf211045387, moduleTitle=阿斯利康卵巢癌新药获FDA批准！, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=cdf211045387)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1989739, encodeId=32aa1989e39f9, content=<a href='/topic/show?id=05ac3686ec6' target=_blank style='color:#2F92EE;'>#卵巢癌新药#</a>, objectTitle=晚期卵巢癌患者福音！二代测序助力FDA加速批准卵巢癌新药, objectType=article, longId=85280, objectId=040d85280b1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=040d85280b1, replyNumber=0, likeNumber=36, createdTime=2017-11-29, rootId=0, userName=lisa438, userId=373b263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=040d85280b1, moduleTitle=晚期卵巢癌患者福音！二代测序助力FDA加速批准卵巢癌新药, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=040d85280b1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1989740, encodeId=a02a1989e4045, content=<a href='/topic/show?id=05ac3686ec6' target=_blank style='color:#2F92EE;'>#卵巢癌新药#</a>, objectTitle=卵巢癌新药olaparib获3期临床突破, objectType=article, longId=92108, objectId=5ff2921087a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5ff2921087a, replyNumber=0, likeNumber=38, createdTime=2017-12-09, rootId=0, userName=lisa438, userId=373b263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5ff2921087a, moduleTitle=卵巢癌新药olaparib获3期临床突破, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5ff2921087a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1989741, encodeId=8a241989e41e3, content=<a href='/topic/show?id=05ac3686ec6' target=_blank style='color:#2F92EE;'>#卵巢癌新药#</a>, objectTitle=FDA批准第三个PARPi卵巢癌新药niraparib, objectType=article, longId=93844, objectId=f2fd938442c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=f2fd938442c, replyNumber=0, likeNumber=38, createdTime=2017-12-12, rootId=0, userName=lisa438, userId=373b263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=f2fd938442c, moduleTitle=FDA批准第三个PARPi卵巢癌新药niraparib, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=f2fd938442c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1989738, encodeId=2e921989e383e, content=<a href='/topic/show?id=05ac3686ec6' target=_blank style='color:#2F92EE;'>#卵巢癌新药#</a>, objectTitle=JCO：卵巢癌新药Farletuzumab三期临床试验结果发表，3年前已完成试验，结果阴性, objectType=article, longId=65679, objectId=6781656e9f0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=6781656e9f0, replyNumber=0, likeNumber=32, createdTime=2016-09-29, rootId=0, userName=lisa438, userId=373b263, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=6781656e9f0, moduleTitle=JCO：卵巢癌新药Farletuzumab三期临床试验结果发表，3年前已完成试验，结果阴性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=6781656e9f0)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

卵巢癌新药

2020-05-29

lisa438 (审核中...)

前往app查看评论内容

#卵巢癌新药#

卵巢癌新药纳入医保专家：患者月均自付费用低至两三千元

2022-02-07

lisa438 (审核中...)

前往app查看评论内容

#卵巢癌新药#

阿斯利康卵巢癌新药获FDA批准！

2017-10-08

lisa438 (审核中...)

前往app查看评论内容

#卵巢癌新药#

晚期卵巢癌患者福音！二代测序助力FDA加速批准卵巢癌新药

2017-11-29

lisa438 (审核中...)

前往app查看评论内容

#卵巢癌新药#

卵巢癌新药olaparib获3期临床突破

2017-12-09

lisa438 (审核中...)

前往app查看评论内容

#卵巢癌新药#

FDA批准第三个PARPi卵巢癌新药niraparib

2017-12-12

lisa438 (审核中...)

前往app查看评论内容

#卵巢癌新药#

JCO：卵巢癌新药Farletuzumab三期临床试验结果发表，3年前已完成试验，结果阴性

2016-09-29

科室
- - 订阅+
  - 更多科室
工具
服务